Organizing Pneumonia Induced by Inhalation of Interferon in the Treatment of Lung Adenocarcinoma: One Case Report and Literature Review_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

DuanLinli , ZhouYing , ZhangNuofu ,  LiuChunli

The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, Guangzhou, Guangdong, 510120, China;

Corresponding author：

LiuChunli, Email: chunli@gird.cn

Keywords：

Aerosolized interferon; Drug-induced lung injury; Lung adenocarcinoma

DOI：

10.7507/1671-6205.2015140

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To evaluate the clinical manifestation, radiological, pathological features and treatment of organizing pneumonia (OP) induced by aerosolized recombinant super compound interferon (rSIFN-co). Methods Clinical features and related laboratory examinations of a patient with OP developing after initiation of rSIFN-co for treatment of lung adenocarcinoma were analyzed, and the relevant literature was reviewed. Results A 48-year-old man developed cough, fevers, shortness of breath and weight loss, shortly half a month after initiation of therapy with rSIFN-co for lung adenocarcinoma. Chest high resolution computerized tomography (HRCT) showed multiple lung infection diseases. However, the anti-infection treatment was invalid. Lung tissue biopsy by bronchofibroscope was consistent with OP. After discontinuation of rSIFN-co and receiving pulse corticosteroid therapy followed by oral methylprednisolone, the pneumonic symptoms and chest manifestations markedly improved. After eight-month follow-up, the patient's condition was stable. The relative literature screening from Pubmed and Wanfangdata was implemented, but there was no report about OP caused by aerosolized rSIFN-co for lung adenocarcinoma. Conclusion This report suggests that treatment with aerosolized rSIFN-co for lung adenocarcinoma may induce OP, a rare complication, and clinicians should have vigilance on it.

Citation： DuanLinli, ZhouYing, ZhangNuofu, LiuChunli. Organizing Pneumonia Induced by Inhalation of Interferon in the Treatment of Lung Adenocarcinoma: One Case Report and Literature Review. Chinese Journal of Respiratory and Critical Care Medicine, 2015, 14(6): 583-587. doi: 10.7507/1671-6205.2015140 Copy

1.	Strober W, Fuss I, Kitani A. Regulation of experimental mucosal inflammation. Acta Odontol Scand,2001,59:244-247.
2.	Sun H, Gutierrez P, Jackson MJ, et al. Essential role of nitric oxide and interferon-gamma for tumor immunotherapy with interleukin-10. J Immunother,2000,23:208-214.
3.	Becker C, Pohla H, Frankenberger B, et al. Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat Med,2001,7:1159-1162.
4.	陈妍,何跃东,潘小玲,等.重组高效复合干扰素增强宫颈癌CaSki细胞对CTL杀伤作用敏感性及机制的研究.四川大学学报(医学版),2008,39:715-718.
5.	郑洁,吕青,魏大鹏.重组复合高效干扰素抗人乳腺癌细胞的体外实验研究.四川大学学报(医学版),2010,41:29-34,48.
6.	谭秀梅,何凯,高德红,等.新型重组高效复合干扰素对卵巢癌细胞的生长抑制及促凋亡作用.中国性科学,2011,20:5-7,9.
7.	Vahid B, Esmaili A. Erlotinib-associated acute pneumonitis:report of two cases. Can Respir J,2007,14:167-170.
8.	Smith J. Erlotinib:small-molecule targeted therapy in the treatment of non-small-cell lung cancer. Clin Ther,2005,27:1513-1534.
9.	Raanani P, Ben-Bassat I. Immune-mediated complications during interferon therapy in hematological patients. Acta Haematol,2002,107:133-144.
10.	Ando S, Kawai K, Kuriyagawa K, et al. Extremely acute exacerbation of interstitial Pneumonia after interferon-alpha treatment for metastatic renal cell carcinoma. Int J Clin Oncol,2009,14:171-173.
11.	施举红,严晓伟,许文兵,等.药物性肺损伤的临床诊断与治疗.中华结核和呼吸杂志,2007,30:161-166.
12.	Patel M, Ezzat W, Pauw KL, et al. Bronchiolitis obliterans organizing pneumonia in a patient with chronic myelogenous leukemia developing after initiation of interferon and cytosine arabinoside. Eur J Haematol,2001,67:318-321.

1. Strober W, Fuss I, Kitani A. Regulation of experimental mucosal inflammation. Acta Odontol Scand,2001,59:244-247.
2. Sun H, Gutierrez P, Jackson MJ, et al. Essential role of nitric oxide and interferon-gamma for tumor immunotherapy with interleukin-10. J Immunother,2000,23:208-214.
3. Becker C, Pohla H, Frankenberger B, et al. Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat Med,2001,7:1159-1162.
4. 陈妍,何跃东,潘小玲,等.重组高效复合干扰素增强宫颈癌CaSki细胞对CTL杀伤作用敏感性及机制的研究.四川大学学报(医学版),2008,39:715-718.
5. 郑洁,吕青,魏大鹏.重组复合高效干扰素抗人乳腺癌细胞的体外实验研究.四川大学学报(医学版),2010,41:29-34,48.
6. 谭秀梅,何凯,高德红,等.新型重组高效复合干扰素对卵巢癌细胞的生长抑制及促凋亡作用.中国性科学,2011,20:5-7,9.
7. Vahid B, Esmaili A. Erlotinib-associated acute pneumonitis:report of two cases. Can Respir J,2007,14:167-170.
8. Smith J. Erlotinib:small-molecule targeted therapy in the treatment of non-small-cell lung cancer. Clin Ther,2005,27:1513-1534.
9. Raanani P, Ben-Bassat I. Immune-mediated complications during interferon therapy in hematological patients. Acta Haematol,2002,107:133-144.
10. Ando S, Kawai K, Kuriyagawa K, et al. Extremely acute exacerbation of interstitial Pneumonia after interferon-alpha treatment for metastatic renal cell carcinoma. Int J Clin Oncol,2009,14:171-173.
11. 施举红,严晓伟,许文兵,等.药物性肺损伤的临床诊断与治疗.中华结核和呼吸杂志,2007,30:161-166.
12. Patel M, Ezzat W, Pauw KL, et al. Bronchiolitis obliterans organizing pneumonia in a patient with chronic myelogenous leukemia developing after initiation of interferon and cytosine arabinoside. Eur J Haematol,2001,67:318-321.

Chinese Journal of Respiratory and Critical Care Medicine

Organizing Pneumonia Induced by Inhalation of Interferon in the Treatment of Lung Adenocarcinoma: One Case Report and Literature Review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content